Myriad is continuing its mission to expand its companion diagnostics reach by teaming up with Tesaro and Merck to evaluate their breast and ovarian cancer drugs, and expanding its partnership with Abbvie into lung cancer. .
Myriad Genetics Inc. furthered its companion diagnostics cancer play with a new collaboration with drug firms and the expansion of an existing partnership.
Myriad announced Feb. 22 that it has inked a deal with Tesaro Inc. and Merck & Co. Inc. to use Myriad's myChoice HRD (homologous recombination deficient) diagnostic offering...
The brunt of the tariff exposure stems from Singapore and Costa Rica, which together account for an estimated 70% to 80% of the tariff-related cost burden. Less than 10% of the exposure is tied to China.
A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.
The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.
